| Followers | 226 |
| Posts | 11454 |
| Boards Moderated | 6 |
| Alias Born | 06/22/2009 |
Friday, June 30, 2023 11:52:31 AM
Bounce starting.
Come visit my boards:
Shankapotamus' Playpen
Stocktamer Board
Recent BTAI News
- BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting • GlobeNewswire Inc. • 05/28/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 11:02:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 11:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 11:00:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 08:29:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 08:27:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 08:26:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 11:07:13 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 11:05:50 AM
- BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/15/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:01:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:00:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:00:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/17/2026 09:00:30 PM
- BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting • GlobeNewswire Inc. • 04/17/2026 11:00:00 AM
- BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions • GlobeNewswire Inc. • 04/08/2026 11:00:00 AM
- BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting • GlobeNewswire Inc. • 04/01/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 10:58:25 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/27/2026 09:10:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 11:21:25 AM
- BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting • GlobeNewswire Inc. • 03/27/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 12:05:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 12:03:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 12:01:16 AM
- BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering • GlobeNewswire Inc. • 03/11/2026 08:20:00 PM
